The breadth of C-suite selling without 10b5-1 plans warrants monitoring for upcoming catalysts or data readouts. The next major event is likely the Q3 earnings release or clinical data update; watch for any pre-announcement or guidance change.
Price Chart
Executive Summary
Seven insiders at Revolution Medicines, including the CFO, COO, and General Counsel, collectively sold approximately $7.8 million in open-market stock on September 16, 2026. While the dollar value is modest relative to the company's market cap, the breadth of C-suite participation and the absence of 10b5-1 plan indications make this a notable bearish signal.
Key Financial Metrics
Key Facts
- Seven insiders sold shares on September 16, 2026, totaling ~$7.8 million in open-market sales.
- Participants include CFO Jack Anders, COO Horn Margaret A., SVP & General Counsel Cislini Jeff, and Chief Development Officer Sandler Alan B.
- No 10b5-1 plan indication was noted for any of the sales.
- The total sale value represents approximately 0.24% of the company's market cap (based on ~$3.3B market cap at $195/share).
- The cluster is concentrated on a single day, suggesting a coordinated event or common liquidity need rather than routine diversification.
Financial Impact
~$7.8 million in insider sales, ~0.24% of market cap
Risk Factors
- Insider selling may signal management's view that the stock is fully valued or that near-term catalysts are uncertain.
- Concentrated selling by multiple senior officers could precede negative clinical or regulatory news.
- The absence of any insider buying alongside the sales reinforces the bearish signal.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RVMD-1790114462765 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | Institutional Cluster | $186.99 | awaiting T+60 | — | $183.90 (−1.65%) |
Oct 21, 2026 5d ago | Press Release | $187.69 | awaiting T+60 | — | $183.90 (−2.02%) |
Oct 13, 2026 13d ago | 8-K | $193.52 | awaiting T+60 | — | $183.90 (−4.97%) |
Oct 12, 2026 14d ago | Institutional Cluster | $193.95 | awaiting T+60 | — | $183.90 (−5.18%) |
Oct 1, 2026 25d ago | Insider Cluster | $206.64 | awaiting T+60 | — | $183.90 (−11.00%) |
Sep 29, 2026 27d ago | Insider Cluster | $205.26 | awaiting T+60 | — | $183.90 (−10.41%) |
Sep 28, 2026 28d ago | Insider Cluster | $204.48 | awaiting T+60 | — | $183.90 (−10.06%) |
Sep 24, 2026 4w ago | Insider Cluster | $204.97 | awaiting T+60 | — | $183.90 (+10.28%) |
Sep 22, 2026 4w ago | Insider Cluster | $190.74 | awaiting T+60 | — | $183.90 (+3.59%) |
Sep 18, 2026 5w ago | Insider Cluster | $192.76 | awaiting T+60 | — | $183.90 (+4.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers